Aortic Valve Stenosis

Rates of reintervention and other outcomes varied widely across surgical aortic valve models, with the Perimount models having the best performance, researchers reported in JAMA Network Open.

Today is Heart Valve Disease Awareness Day, which serves as a reminder that while many advancements have been made in the treatment of heart valve disease, not all patients have been able to take advantage of them.

Homozygous familial hypercholesterolemia, although rare, is frequently undertreated, especially in non-high-income countries, and is sometimes diagnosed after atherosclerosis or aortic stenosis is already present, researchers reported.

Procedural time of day appeared to have no influence on 2-year outcomes among intermediate-to-high-risk patients who underwent elective surgical or transcatheter aortic valve replacement, researchers reported.

In an economic analysis from the PARTNER 3 trial, transcatheter aortic valve replacement was economically dominant compared with surgery at 2 years in patients with severe aortic stenosis at low surgical risk.

Transcatheter aortic valve replacement with a self-expanding valve was noninferior to surgical AVR in intermediate-risk patients at 5 years, according to new data from the SURTAVI trial.

Excess CV mortality due to the pandemic has been observed globally, and clinicians may need to consider restructuring services to meet the backlog of patients on the waiting list to undergo lifesaving interventions, a speaker reported.

The early days of the COVID-19 pandemic challenged interventional cardiologists in unexpected ways, including the disruption of all aspects of care and the halting of most transcatheter aortic valve replacements.

Amid positive results from large clinical trials confirming the benefits of transcatheter aortic valve replacement, along with expanded indications from the FDA, recently updated recommendations represent the already widespread acceptance of less invasive interventions for aortic stenosis.

A vessel preparation system involving microincisions used before endovascular treatment for peripheral artery disease was associated with good outcomes at 1 year, researchers reported.